Allgemeine Gynäkologie / Prävention – Was gibt es Neues zur Vorhersage der Präeklampsie?

• Literatur

• 1 Khan KS, Wojdyla D, Say L et al. WHO analysis of causes of maternal death: a systematic review. Lancet 2006; 367: 1066-1074
• 2 Zhang J, Klebanoff M, Roberts J. Prediction of adverse outcomes by common definitions of hypertension in pregnancy. Obstet Gynecol 2001; 97: 261-267
• 3 Fisher KA, Luger A, Spargo BH et al. Hypertension in pregnancy: clinical-pathological correlations and remote prognosis. Medicine (Baltimore) 1981; 60: 267-276
• 4 Maynard SE, Min J-Y, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658
• 5 Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683
• 6 Verlohren S, Galindo A, Schlembach D et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010; 202: 161.e1-11
• 7 Verlohren S, Herraiz I, Lapaire O et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 2014; 63: 346-652
• 8 Verlohren S, Herraiz I, Lapaire O et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012; 206: 58.e1-8
• 9 Zeisler H, Hund M, Verlohren S. The sFlt-1: PlGF ratio in women with suspected preeclampsia. N Engl J Med 2016; 374: 1785-1786